News
The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...
Biopharmaceuticals stock Gilead Sciences ( GILD 3.08%) jumped 2.5% through 12:30 p.m. ET Friday after Needham & Co. upgraded ...
Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...
1d
GlobalData on MSNGilead wins positive European approval opinion for twice-yearly HIV injection
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...
Now, it’s worth noting Stock Advisor’s total average return is 1,041% — a market-crushing outperformance compared to 183 % ...
AbbVie, Gilead Sciences and GSK marked World Hepatitis Day on Monday, outlining the need to tackle the stigma and discrimination associated with the group of viruses to eliminate them as a public ...
Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...
Gilead Sciences Inc. closed 4.78% short of its 52-week high of $119.96, which the company achieved on March 10th.
4d
Fintel on MSNNeedham Upgrades Gilead Sciences (GILD)
Fintel reports that on July 25, 2025, Needham upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results